The residual efficacy of pyriproxyfen against Aedes aegypti (L.) was examined by treating 2-liter buckets with a range of rates of Sumilarv 0.5G (1 00, 10, 1, and 04 mg product/liter or nominal dose of 500, 50, 5, and 0.5 ppb active ingredient) under semifield conditions. Approximately every 2 wk, pupal emergence inhibition (EI) was measured by using Cairns colony Ae. aegypti. Pooled water samples from the five replicate buckets were analyzed for active pyriproxyfen by using ultra-high-pressure liquid chromatography with tandem mass spectrometry detection. A strong dose—response in EI was exhibited, with the 0.1 mg/liter giving ≈50% EI for only the initial week, whereas the 10 and 100 mg/liter doses produced EI > 90% for 8 and 40 wk, respectively. Measurable levels of active ingredient were detected in the 100, 10, and 1 mg/liter treatments, with measured starting concentrations of just 1-2-1.4% of the delivered (active ingredient) dose. Pyriproxyfen was detected in the 100 mg/liter treatment through the entire course of the trial (60 wk).
How to translate text using browser tools
1 September 2013
Residual Treatment of Aedes aegypti (Diptera: Culicidae) in Containers Using Pyriproxyfen Slow-Release Granules (Sumilarv 0.5G)
Scott A. Ritchie,
Chris Paton,
Tamara Buhagiar,
Garry A. Webb,
Vladan Jovic
ACCESS THE FULL ARTICLE
It is not available for individual sale.
This article is only available to subscribers.
It is not available for individual sale.
It is not available for individual sale.
Journal of Medical Entomology
Vol. 50 • No. 5
September 2013
Vol. 50 • No. 5
September 2013
Aedes aegypti
dose—response
persistence
pyriproxyfen
Sumilarv